drug discovery News

Kolkata, India, February 17, 2012: TCG Lifesciences Limited (“TCGLS”) announced the nomination of a pre-clinical development candidate (“Candidate”) under a R&D collaboration entered into in 2009 with Pfizer Inc. (“Pfizer”).

Cambridge Healthtech Institute & Bio-IT World organizes a dinner short course on June 6, 2012 at the Royal Sonesta Hotel Boston in Cambridge, MA. The course will be held at the conclusion of day one of the Structure-Based Drug Design conference.

CHI’s Cancer Biologics conference is a 3-day event based on in-depth research with experts in the field.

Hear Drug Discovery Leaders at the Upcoming Molecular Medicine Tri-Conference

This Insight Pharma Report focuses on the applications, technology and market aspects of high-content analysis.

Cambridge Healthtech Institute just adds an interactive panel discussion to take place at its Integrated R&D Informatics & Knowledge Management conference on Feb. 21-23, 2012, San Francisco, CA.

Discussions led by industry experts, such as Malcolm Young (e-Therapeutics), Jeremy Jenkins (Novartis), and John Burke (Boehringer Ingleheim) will address the implementation of de-risking approaches into the corporate organization.

TCG Lifesciences Limited (TCGLS) has announced that it has entered into a strategic agreement with JSW Lifesciences (JSW), a full services EU based CRO, to strengthen its R&D offerings in the area of Central Nervous System (CNS).

A 2-day Symposium on "Cloud Computing: Applications and Advances in Life Sciences R&D" will take place on Feb. 19-20, 2012 at the InterContinental Hotel, San Francisco. This symposium is part of many offerings at the Molecular Med TRI-CON 2012.

Christopher P. Austin, M.D., Scientific Director, NIH Center for Translational Therapeutics, will deliver the keynote presentation at CHI’s Predictive Functional Human Tissue Models conference scheduled on November 17-18, 2011, Boston, MA.

Peptides International in partnership with Baylor University secures highly sought-after NIH RO1 grant

Peptides International announces publication of peer-reviewed scientific paper outlining possible applications of peptide toxins for drug discovery relating to autoimmune diseases.

IQPC’s Drug Discovery Summit brings industry experts together to investigate and share approaches and solutions for streamlining drug discovery to development

Progenra, Inc., announced today that their UbiPro™ Drug Discovery Platform is available for licensing to partners interested in discovering drugs that modify the ubiquitin-proteasome pathway.

IQPC’s 7th Annual Compound Management & Integrity Summit brings together Pharmaceutical Professionals, Clinical Research Organizations and Industry Experts to address evolving industry concerns

Keeping up with the flood of scientific information has been challenging, Spotting patterns & extracting useful information has been even harder. DocumentLens™ makes it easier to gain insightful knowledge from information and to share & collaborate

Kolkata, India, February 17, 2012: TCG Lifesciences Limited (“TCGLS”) announced the nomination of a pre-clinical development candidate (“Candidate”) under a R&D collaboration entered into in 2009 with Pfizer Inc. (“Pfizer”).

Cambridge Healthtech Institute & Bio-IT World organizes a two hour dinner short course on June 7, 2012, Royal Sonesta Hotel Boston, Cambridge, MA. The course will be held at the conclusion of day two of the Structure-Based Drug Design conference.

Cambridge Healthtech Institute & Bio-IT World organizes a dinner short course on June 6, 2012 at the Royal Sonesta Hotel Boston in Cambridge, MA. The course will be held at the conclusion of day one of the Structure-Based Drug Design conference.

Join us for a roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Discussion moderated by: Norman J. Maitland, Ph.D., Chief Scientific Officer, Procure Therapeutics Ltd.

Join 150+ delegates involved in IT and informatics at pharma, biotech & academic institutions at CHI’s Molecular Med TRI-CON 2012 event on Feb. 21-23, 2012 at the Moscone North Convention Center in San Francisco, CA. www.TriConference.com/IRD.

TCG Lifesciences Limited (TCGLS) announced the achievement of two distinct milestones in their ongoing drug discovery partnership with Endo Pharmaceuticals. TCGLS will receive undisclosed success fees against these milestones.

A roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Moderated by: Ho Sung Cho, Ph.D., Chief Technical Officer, Ambrx.

CHI's Fifth Annual Protein-Protein Interactions: Targeting PPI for Therapeutic Interventions will be held April 18-19, 2012 in San Diego as part of the Drug Discovery Chemistry conference. Early registration discount ends January 27th.

A roundtable discussion during the Cancer Biologics Conference at the Tri-Conference. Moderatored by: Gary Starling, Ph.D., Director, GPRD Discovery, Oncology Biologics, Abbott Biotherapeutics Corp.

CHI’s Cancer Biologics conference is a 3-day event based on in-depth research with experts in the field.

Peptides International announces new management structure, including new President and Chief Operating officers, and Vice President, following very successful year and expanded opportunities, especially in custom peptide synthesis.

Hear Drug Discovery Leaders at the Upcoming Molecular Medicine Tri-Conference

LifeSensors, Inc. announced today that they have appointed Dr. Mark Engleka to the position of Sales and Marketing Director.

Chris Porter, Product Manager, HPC Cloud, will lead a luncheon presentation at CHI’s Cloud Computing: Applications and Advances in Life Sciences R&D Symposium next month in San Francisco, CA.

This Insight Pharma Report focuses on the applications, technology and market aspects of high-content analysis.

Imaging in Cancer Drug Development will offer an excellent arena to discuss challenges, compare techniques and gain valuable information on how this field is developing and how advances may be of benefit in the future.

Cambridge Healthtech Institute just adds an interactive panel discussion to take place at its Integrated R&D Informatics & Knowledge Management conference on Feb. 21-23, 2012, San Francisco, CA.

Grenoble, France – CYTOO SA announced today the closing of a series C funding round of USD 10M (EUR 7M). New investors, Sham and Entrepreneurs Fund (EF), led the round. Existing investors AURIGA Partners and Jacques Lewiner also participated.

Discussions led by industry experts, such as Malcolm Young (e-Therapeutics), Jeremy Jenkins (Novartis), and John Burke (Boehringer Ingleheim) will address the implementation of de-risking approaches into the corporate organization.

TCG Lifesciences Limited (TCGLS) has announced that it has entered into a strategic agreement with JSW Lifesciences (JSW), a full services EU based CRO, to strengthen its R&D offerings in the area of Central Nervous System (CNS).

G-Protein-Coupled Receptors are the Most Diverse Type of Receptors in the Human Body

Drug repositioning offers the possibility of breathing new life into pharmaceutical R&D. By recycling drug data, repositioning promises to boost production, accelerate and derisk R&D, and enhance product life-cycle management.

A 2-day Symposium on "Cloud Computing: Applications and Advances in Life Sciences R&D" will take place on Feb. 19-20, 2012 at the InterContinental Hotel, San Francisco. This symposium is part of many offerings at the Molecular Med TRI-CON 2012.

GlobalData’s “Biomarkers in Drug Discovery - Earlier Usage of Biomarkers in Optimization Stage to Reduce Drug Attrition Rate Significantly” is now available at ReportsnReports.com.

Christopher P. Austin, M.D., Scientific Director, NIH Center for Translational Therapeutics, will deliver the keynote presentation at CHI’s Predictive Functional Human Tissue Models conference scheduled on November 17-18, 2011, Boston, MA.

Tecan brings HP Direct Digital Titration to drug discovery biologists

Peptides International in partnership with Baylor University secures highly sought-after NIH RO1 grant

Peptides International announces publication of peer-reviewed scientific paper outlining possible applications of peptide toxins for drug discovery relating to autoimmune diseases.

IQPC’s Drug Discovery Summit brings industry experts together to investigate and share approaches and solutions for streamlining drug discovery to development

Progenra, Inc., announced today that their UbiPro™ Drug Discovery Platform is available for licensing to partners interested in discovering drugs that modify the ubiquitin-proteasome pathway.

IQPC’s 7th Annual Compound Management & Integrity Summit brings together Pharmaceutical Professionals, Clinical Research Organizations and Industry Experts to address evolving industry concerns

Isogenica, Biolauncher and Cresset Biomolecular Discovery forge alliance to bring powerful target-to-drugs platform to market. Joint venture aims to rapidly identify small molecule therapeutics to pharma targets.

New high-throughput screening assay exploits transfer RNA (tRNA) as a target for inhibition...

Genetic Engineering & Biotechnology News (GEN) will host a Contract Services Summit and Drug Discovery Theater at the Annual BIO International conference in Washington, DC, later this month.

Keeping up with the flood of scientific information has been challenging, Spotting patterns & extracting useful information has been even harder. DocumentLens™ makes it easier to gain insightful knowledge from information and to share & collaborate

Addgene connects with the DECIPHER Project to help distribute shRNA Libraries to the scientific community

Cambridge Healthtech Institute announces two of the largest molecular imaging societies are sponsoring its In Vivo Molecular Imaging in Drug Discovery & Development event on June 8 – 9, in Philadelphia, as part of its World Pharma Congress.

User-focused portal offers live experience for Aureus Sciences’ applications, tools and content, helping scientists to accelerate drug discovery with data they can trust.

SMi’s Biobanking conference, taking place in London, 11th & 12th July 2011, is the perfect opportunity to network with the industry’s leading figures and contribute to the successful future of drug discovery.

CHI and Bio-IT World's "Structure-Based Design" Conference to be held on June 8-10, 2011 in Cambridge, MA, will feature a new session: New Targets and Drug Modalities

A US drug discovery company has found a single instrument that meets all its requirements for radio TLC scanning and radio HPLC detection - the dual-system Scan-RAM 1B from LabLogic Systems.

CHI and Bio-IT World's "Structure-Based Design" Conference to be held on June 8-10, 2011 in Cambridge, MA, will feature a new session: Protein Flexibility and Druggability

Euroscreen S.A., a pre-clinical drug discovery company based in Gosselies, Belgium, has chosen Tecan’s flexible Infinite® F200 PRO multimode plate reader for a variety of screening applications in drug discovery and characterization.

Promising Assays and Technologies for Better Pre-Clinical Predictions

“Intense” just might be the best term to describe the biotech industry’s pursuit of novel biomarkers for new drug discovery and development efforts

350 Speaker presentations are available on CD from Cambridge Healthtech Institute’s past event, Molecular Med TRI-CON, which took place on February 23-25, 2011 in San Francisco, CA (www.TriConference.com)

Featuring Keynote from the President’s Council of Advisors on Science and Technology Dr. David E. Shaw and Other Internationally Recognized Experts

Patented algorithm enables new optical diagnostic tools for disease detection...

BioAtla and Charles River have partnered to create an integrated biological service for antibodies and other protein therapeutics designed to accelerate drug development for customers from the earliest stages of discovery all the way through IND.

Oncology is the Key Therapeutic Segment of the Early Stage Drug Pipeline